Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Researchers at the University of Oxford have launched a human challenge trial to look at what kind of immune response can stop people from becoming re-infected. They also want to see how the immune system reacts second time round. A human challenge trial in medical research is a carefully controlled study that involves purposefully infecting a subject with a pathogen or bug, in order to study the effects of that infection.

The study will take place in two phases with different participants in each phase. The first phase, which will start in April 2021, will establish the lowest dose of virus which, in approximately 50% of people who have previously been naturally infected, can take hold and start replicating but produce little or no symptoms. In the second phase of the study, expected to start in summer 2021, all participants will be infected with the standardised dose of virus which was established in phase one.

Read the full news article on the University of Oxford website

Similar stories

Removing bias from healthcare AI tools

Rapid advances in Artificial Intelligence (AI) have opened the way for the creation of a huge range of new healthcare tools, but to ensure that these tools do not exacerbate pre-existing health inequities, researchers urge the use of more representative data in their development.